Table 3 Impact of CaPa treatment on the expression of hallmark genes of resistance/sensitivity to immune checkpoint inhibitors
From: Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Genes | Log2 fold change | P value | Adjusted p value |
|---|---|---|---|
CD274 | 2.75 | 7.21e-22 | 2,40E-19 |
NECTIN4 | 4.35 | 2.38e-18 | 4,97E-16 |
HMGB1 | −0.99 | 4.72e-09 | 2,13E-07 |
TNFSF4 | −1.03 | 0.0008 | 0,008 |
TNFSF18 | −1.72 | 0.003 | 0,028 |
NT5E | 0.73 | 0.005 | 0,037 |
HLA-A | −1.04 | 0.006 | 0,043 |
HLA-C | −0.40 | 0.010 | 0,058 |
B2M | −0.28 | 0.01 | 0,086 |
HLA-E | −0.33 | 0.04 | 0,171 |
HLA-B | −0.24 | 0.13 | 0,356 |
PVR | 0.69 | 0.13 | 0,366 |
ICOSLG | 0.93 | 0.24 | 0,524 |
NECTIN3 | 0.37 | 0.34 | 0,621 |
SELPLG | −0.33 | 0.54 | 0,778 |
NECTIN2 | −0.08 | 0.72 | 0,886 |
CD276 | −0.073 | 0.86 | 0,944 |
CD47 | 0.003 | 0.99 | 0,997 |
CEACAM1 | 1.82 | 0.12 | NA |
TNFRSF14 | 1.09 | 0.28 | NA |